983 research outputs found
Modelling neurological diseases in large animals: Criteria for model selection and clinical assessment
Longâterm cardiovascular effects of vandetanib and pazopanib in normotensive rats
Vandetanib and pazopanib are clinically available, multiâtargeted inhibitors of vascular endothelial growth factor (VEGF) and plateletâderived growth factor (PDGF) receptor tyrosine kinases. Shortâterm VEGF receptor inhibition is associated with hypertension in 15%â60% of patients, which may limit the use of these anticancer therapies over the longer term. To evaluate the longerâterm cardiovascular implications of treatment, we investigated the âonââtreatment (21 days) and âoffââtreatment (10 days) effects following daily administration of vandetanib, pazopanib, or vehicle, in conscious rats. Cardiovascular variables were monitored in unrestrained SpragueâDawley rats instrumented with radiotelemetric devices. In Study 1, rats were randomly assigned to receive either daily intraperitoneal injections of vehicle (volume 0.5 mL; n = 5) or vandetanib 25 mg/kg/day (volume 0.5 mL; n = 6). In Study 2, rats received either vehicle (volume 0.5 mL; n = 4) or pazopanib 30 mg/kg/day (volume 0.5 mL; n = 7), dosed once every 24 hours for 21 days. All solutions were in 2% Tween, 5% propylene glycol in 0.9% saline solution. Vandetanib caused sustained increases in mean arterial pressure (MAP), systolic blood pressure (SBP), and diastolic blood pressure (DBP) compared to baseline and vehicle. Vandetanib also significantly altered the circadian cycling of MAP, SBP, and DBP. Elevations in SBP were detectable 162 hours after the last dose of vandetanib. Pazopanib also caused increases in MAP, SBP, and DBP. However, compared to vandetanib, these increases were of slower onset and a smaller magnitude. These data suggest that the cardiovascular consequences of vandetanib and pazopanib treatment are sustained, even after prolonged cessation of drug treatment
Occupancy of chromatin organizers in the EpsteinâBarr virus genome
AbstractThe human CCCTC-binding factor, CTCF, regulates transcription of the double-stranded DNA genomes of herpesviruses. The architectural complex cohesin and RNA Polymerase II also contribute to this organization. We profiled the occupancy of CTCF, cohesin, and RNA Polymerase II on the episomal genome of the EpsteinâBarr virus in a cell culture model of latent infection. CTCF colocalizes with cohesin but not RNA Polymerase II. CTCF and cohesin bind specific sequences throughout the genome that are found not just proximal to the regulatory elements of latent genes, but also near lytic genes. In addition to tracking with known transcripts, RNA Polymerase II appears at two unannotated positions, one of which lies within the latent origin of replication. The widespread occupancy profile of each protein reveals binding near or at a myriad of regulatory elements and suggests context-dependent functions
Probe dependence of allosteric enhancers on the binding affinity of adenosine A1âreceptor agonists at rat and human A1âreceptors measured using NanoBRET
Background and Purpose: Adenosine is a local mediator that regulates a number of physiological and pathological processes via activation of adenosine A1âreceptors. The activity of adenosine can be regulated at the level of its target receptor via drugs that bind to an allosteric site on the A1âreceptor. Here, we have investigated the species and probe dependence of two allosteric modulators on the binding characteristics of fluorescent and nonfluorescent A1âreceptor agonists. Experimental Approach: A Nanoâluciferase (Nluc) BRET (NanoBRET) methodology was used. This used Nâterminal Nlucâtagged A1âreceptors expressed in HEK293T cells in conjunction with both fluorescent A1âreceptor agonists (adenosine and NECA analogues) and a fluorescent antagonist CA200645.Key Results: PD 81,723 and VCP171 elicited positive allosteric effects on the binding affinity of orthosteric agonists at both the rat and human A1âreceptors that showed clear probe dependence. Thus, the allosteric effect on the highly selective partial agonist capadenoson was much less marked than for the full agonists NECA, adenosine, and CCPA in both species. VCP171 and, to a lesser extent, PD 81,723, also increased the specific binding of three fluorescent A1âreceptor agonists in a speciesâdependent manner that involved increases in Bmax and pKD.Conclusions and Implications: These results demonstrate the power of the NanoBRET ligandâbinding approach to study the effect of allosteric ligands on the binding of fluorescent agonists to the adenosine A1âreceptor in intact living cells. Furthermore, our studies suggest that VCP171 and PD 81,723 may switch a proportion of A1âreceptors to an active agonist conformation (R*)
The effect of two selective A1-receptor agonists and the bitopic ligand VCP746 on heart rate and regional vascular conductance in conscious rats
Background and purposeAdenosine is a local mediator that regulates physiological and pathological processes via activation of four G proteinâcoupled receptors (A1, A2A, A2B, A3). We have investigated the effect of two A1âreceptor selective agonists and the novel A1âreceptor bitopic ligand VCP746 on the rat cardiovascular system.Experimental ApproachTo investigate the effect of these A1âagonists on the cardiovascular system, we evaluated their regional haemodynamic responses in conscious rats. Male Sprague Dawley rats (350â450g) were chronically implanted with pulsed Doppler flow probes (positioned around the renal and mesenteric arteries, and the descending abdominal aorta) and catheters (jugular vein and caudal artery). Cardiovascular responses were measured following i.v. infusion (3 min each dose) of CCPA (120, 400, 1200 ng.kgâ1.minâ1), capadenoson or adenosine (30, 100, 300 ÎŒg.kgâ1.minâ1) or VCP746 (6, 20, 60 ÎŒg.kgâ1.minâ1) following preâdosing with DPCPX (0.1 mg.kgâ1 i.v.) or vehicle.Key ResultsCCPA produced a significant A1âreceptorâmediated decrease (p less than 0.05) in heart rate that was accompanied by vasoconstrictions in the renal and mesenteric vascular beds but an increase in hindquarters vascular conductance. The partial agonist capadenoson also produced an A1âreceptorâmediated bradycardia. In contrast, VCP746 produced increases in heart rate and renal and mesenteric vascular conductance that were not mediated by A1âreceptors. In vitro studies confirmed that VCP746 had potent agonist activity at both A2A and A2B receptors.Conclusions and ImplicationsThese results suggest VCP746 mediates its cardiovascular effects via activation of A2 rather than A1 adenosine receptors. This has implications for the design of future bitopic ligands that incorporate A1 allosteric ligand moieties
Involvement of ÎČ-adrenoceptors in the cardiovascular responses induced by selective adenosine A2A and A2B receptor agonists
A2A and A2B adenosine receptors produce regionally selective regulation of vascular tone and elicit differing effects on mean arterial pressure (MAP), whilst inducing tachycardia. The tachycardia induced by the stimulation of A2A or A2B receptors has been suggested to be mediated by a reflex increase in sympathetic activity. Here, we have investigated the role of ÎČ1- and ÎČ2-adrenoceptors in mediating the different cardiovascular responses to selective A2A and A2B receptor stimulation. Hemodynamic variables were measured in conscious male Sprague-Dawley rats (350â450 g) via pulsed Doppler flowmetry. The effect of intravenous infusion (3 min per dose) of the A2A-selective agonist CGS 21680 (0.1, 0.3, 1.0 ”g.kgâ1.minâ1) or the A2B-selective agonist BAY 60â6583 (4.0, 13.3, 40.0 ”g.kgâ1.minâ1) in the absence or following pre-treatment with the non-selective ÎČ-antagonist propranolol (1.0 mg.kgâ1), the selective ÎČ1-antagonist CGP 20712A (200 ”g.kgâ1), or the selective ÎČ2-antagonist ICI 118,551 (2.0 mg.kgâ1) was investigated (maintenance doses also administered). CGP 20712A and propranolol significantly reduced the tachycardic response to CGS 21680, with no change in the effect on MAP. ICI 118,551 increased BAY 60â6583-mediated renal and mesenteric flows, but did not affect the heart rate response. CGP 20712A attenuated the BAY 60â6583-induced tachycardia. These data imply a direct stimulation of the sympathetic activity via cardiac ÎČ1-adrenoceptors as a mechanism for the A2A- and A2B-induced tachycardia. However, the regionally selective effects of A2B agonists on vascular conductance were independent of sympathetic activity and may be exploitable for the treatment of acute kidney injury and mesenteric ischemia
Pentachlorophenol and Cancer Risk: Focusing the Lens on Specific Chlorophenols and Contaminants
COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors
The clinical manifestations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection responsible for coronavirus disease 2019 (COVID-19) commonly include dyspnoea and fatigue, and they primarily involve the lungs. However, extra-pulmonary organ dysfunctions, particularly affecting the cardiovascular system, have also been observed following COVID-19 infection. In this context, several cardiac complications have been reported, including hypertension, thromboembolism, arrythmia and heart failure, with myocardial injury and myocarditis being the most frequent. These secondary myocardial inflammatory responses appear to be associated with a poorer disease course and increased mortality in patients with severe COVID-19. In addition, numerous episodes of myocarditis have been reported as a complication of COVID-19 mRNA vaccinations, especially in young adult males. Changes in the cell surface expression of angiotensin-converting enzyme 2 (ACE2) and direct injury to cardiomyocytes resulting from exaggerated immune responses to COVID-19 are just some of the mechanisms that may explain the pathogenesis of COVID-19-induced myocarditis. Here, we review the pathophysiological mechanisms underlying myocarditis associated with COVID-19 infection, with a particular focus on the involvement of ACE2 and Toll-like receptors (TLRs)
Regionally selective cardiovascular responses to adenosine A2A and A2B receptor activation
Adenosine is a local mediator that regulates changes in the cardiovascular system via activation of four G protein-coupled receptors (A1, A2A, A2B, A3). Here, we have investigated the effect of A2A and A2B-selective agonists on vasodilatation in three distinct vascular beds of the rat cardiovascular system. NanoBRET ligand binding studies were used to confirm receptor selectivity. The regional hemodynamic effects of adenosine A2A and A2B selective agonists were investigated in conscious rats. Male Sprague-Dawley rats (350â450 g) were chronically implanted with pulsed Doppler flow probes on the renal artery, mesenteric artery, and the descending abdominal aorta. Cardiovascular responses were measured following intravenous infusion (3 min for each dose) of the A2A-selective agonist CGS 21680 (0.1, 0.3, 1 ”g kgâ1 minâ1) or the A2B-selective agonist BAY 60-6583 (4,13.3, 40 ”g kgâ1 minâ1) following predosing with the A2A-selective antagonist SCH 58261 (0.1 or 1 mg kgâ1 minâ1), the A2B/A2A antagonist PSB 1115 (10 mg kgâ1 minâ1) or vehicle. The A2A-selective agonist CGS 21680 produced a striking increase in heart rate (HR) and hindquarters vascular conductance (VC) that was accompanied by a significant decrease in mean arterial pressure (MAP) in conscious rats. In marked contrast, the A2B-selective agonist BAY 60-6583 significantly increased HR and VC in the renal and mesenteric vascular beds, but not in the hindquarters. Taken together, these data indicate that A2A and A2B receptors are regionally selective in their regulation of vascular tone. These results suggest that the development of A2B receptor agonists to induce vasodilatation in the kidney may provide a good therapeutic approach for the treatment of acute kidney injury
Investigating the Effects of Homocysteine as an Agonist on Invertebrate Glutamatergic Synapses
Hyperhomocysteinemia (HHcy) in mammals can produce neurological deficits, such as memory loss. The cause of the neurological issues is assumed to be due to homocysteine (HCY) binding to glutamatergic receptors in the central nervous system (CNS). High levels of HCY in the CNS are also associated with Amyotrophic Lateral Sclerosis (ALS) and Parkinsonâs disease. Thus, understanding the detailed mechanisms of HCY in model preparations could be useful in developing potential treatments to neurodegenerative diseases with overlapping symptoms to HHcy. The aim of this study is to investigate the efficacy of HCY as an agonist at glutamatergic synapses in invertebrates. The glutamatergic synapses of the larval Drosophila melanogaster (D. melanogaster) and Procambarus clarkii (P. clarkii) neuromuscular junctions (NMJs) were utilized to examine the effects of applying HCY. Measurements of evoked synaptic transmission in both preparations revealed that 100 mM of HCY did not have any consistent effect. The expectation was that the acute action of HCY would have activated the glutamate receptors and then desensitized them so evoked transmission would be blocked. The pharmacological receptor profile of these NMJ receptors are of a quisqualate subtype and not a kainate, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or N-methyl-D-aspartate receptor (NMDA) subtype. Consequently, HCY may not have any action on quisqualate glutamate receptor subtypes. The findings of this experiments could provide clinical implications regarding relevant pharmacological treatments in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinsonâs disease
- âŠ